rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

ABVC BioPharma, Inc.

ABVC · Nasdaq

Health CareBiotechnologyNot moving yet

ABVC stood above a rising 150-day average in 6 of the last 52 weekly readings, and has been out of that trend for the last 46 weeks. It is 20.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 46
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
14 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 6 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders14+2 on the quarter
New · exited7 · 5
Reported value$1.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026374,499$592K+183,925+96.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026228,042$360K+6,873+3.1%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202697,363$154K00.0%
STATE STREET CORPunchanged · filed 7 Aug 202672,800$115K00.0%
CITADEL ADVISORS LLCnew · filed 14 Aug 202672,091$114K+72,091
BlackRock, Inc.unchanged · filed 7 Aug 202656,442$89K00.0%
NORTHERN TRUST CORPadded · filed 13 Aug 202648,643$77K+16,556+51.6%
XTX Topco Ltdnew · filed 14 Aug 202648,276$76K+48,276
PANAGORA ASSET MANAGEMENT INCnew · filed 6 Aug 202636,682$58K+36,682
UBS Group AGadded · filed 13 Aug 202634,123$54K+32,352+1826.8%
30 Sep 2023 – 30 Jun 2026
61014Sep 23Jun 24Mar 25Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Kevin Patrick Stolz Company insiderVP & Controller · last 27 Jan 20120 · 0
Frank Thomas Krotine Company insiderCOO · last 25 May 20110 · 0
Daniel V. Iannotti Company insiderVP, General Counsel & Secretar · last 11 May 20110 · 0
Robert G. Crockett Company insiderChief Executive Officer · last 11 May 20110 · 0
Sally Judith Ramsey Company insiderVP New Product Development · last 11 May 20112 · 0
James Juliano Company insiderDirector, 10% owner · last 12 Aug 20100 · 0
Joseph Nirta Company insiderDirector · last 11 May 20102 · 0
J.b. Smith Company insiderDirector, 10% owner · last 13 Jan 201014 · 0
Richard Dean Stromback Company insiderDirector, 10% owner · last 2 Oct 20090 · 3

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-48.0%
Debt to equityFY 2025 · to 31 Dec 20250.07×
Research spendFY 2025 · to 31 Dec 202540.9%
Share count trendFY 2025 · to 3 Mar 20261.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$681K

Analyst forecasts

No analyst forecasts yet.